We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Outcome of Antegrade Radical Prostatectomy with Intended Wide Resection in Prostate Cancer Patients with a Preoperative Serum PSA Level >100 ng/ml.
- Authors
Urakami, Shinji; Yonese, Junji; Yamamoto, Shinya; Yuasa, Takeshi; Kitsukawa, Shinichi; Numao, Noboru; Kubo, Yuichi; Ito, Masaya; Sukegawa, Gen; Yasuda, Yosuke; Ishikawa, Yuichi; Fukui, Iwao
- Abstract
Objective: It was the aim of this study to assess the outcome of prostate cancer patients with preoperative prostate-specific antigen (PSA) levels ≥100 ng/ml who were treated with antegrade radical prostatectomy with intended wide resection (aRP). Patients and Methods: Eighteen patients who underwent aRP had an initial PSA level ≥100 ng/ml. Overall survival, disease-specific survival and biochemical progression-free survival (bPFS) rates were determined, and predictors of treatment outcome were examined. Results: The median serum PSA level was 159.5 ng/ml. All patients but one had received neoadjuvant androgen deprivation therapy (ADT), while only 2 patients received adjuvant ADT. Five patients were classified as stage pT2, 6 as pT3a, 6 as pT3b and 1 as pT4. Four patients had locoregional lymph node metastases. Twelve patients developed PSA failure. Eight of them received salvage ADT. The estimated 10-year bPFS rate was 25.0% and the overall survival and disease-specific survival rates were 92.9 and 100%, respectively, at a median follow-up of 6 years. Multivariate analysis revealed only the clinical stage to be predictive of bPFS based on preoperative variables. On the other hand, surgical margin status, extracapsular extension and organ-confined disease were identified as being significant postoperative predictors. Conclusions: This study showed a comparatively satisfactory outcome for clinically non-metastatic prostate cancer with PSA levels ≥100 ng/ml treated by aRP. Copyright © 2011 S. Karger AG, Basel
- Subjects
PROSTATE cancer; PROSTATECTOMY; PROSTATE-specific antigen; SERUM; HEALTH outcome assessment; BIOCHEMISTRY; ADJUVANT treatment of cancer; MULTIVARIATE analysis
- Publication
Urologia Internationalis, 2011, Vol 87, Issue 2, p175
- ISSN
0042-1138
- Publication type
Article
- DOI
10.1159/000328048